Abstract
Purpose
The purpose of this investigator-initiated multicenter phase II study was to determine the activity of the third-generation synthetic anthracycline, amrubicin, administered as second-line therapy in patients with advanced urothelial carcinoma.
Methods
Patients with progressive metastatic urothelial cancer despite first-line chemotherapy were eligible for enrollment. Amrubicin was initially administered at a dose of 40 mg/m2/day daily × 3 every 21 days, and the dose was subsequently reduced to 35 mg/m2/day daily × 3 every 21 days. Prophylactic granulocyte colony-stimulating factor was administered to all patients, and prophylactic antibiotics were administered to patients at high risk of febrile neutropenia. Treatment was administered for up to six cycles in the absence of intolerable toxicity or disease progression. The primary endpoint was the objective response rate.
Results
A total of 22 patients were enrolled. Among the first three patients enrolled, all developed grade 4 neutropenia and one patient died of neutropenic sepsis. The starting dose of amrubicin was subsequently reduced, there were no further episodes of febrile neutropenia, and only one patient required a subsequent dose reduction. The most common adverse events were hematologic; grade ≥3 neutropenia occurred in 27 %, and other grade ≥3 adverse events were uncommon. Partial responses were achieved in three patients [13.6, 95 % confidence interval (CI) 0–28 %), while stable disease was the best response in 12 patients (54.5, 95 % CI 33.7–75.3 %). The trial was closed prematurely due to a development decision by the funder.
Conclusions
Amrubicin as second-line therapy in advanced urothelial carcinoma is associated with modest single-agent activity. While there remains a role for the introduction of novel cytotoxic agents in the management of metastatic urothelial cancer, optimal development of such therapies will likely require patient selection biomarkers.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bellmunt J, von der Maase H, Mead GM et al (2012) Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC intergroup study 30987. J Clin Oncol 30(10):1107–1113. doi:10.1200/JCO.2011.38.6979
Sternberg CN, de Mulder P, Schornagel JH et al (2006) Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42(1):50–54
Sonpavde G, Sternberg CN, Rosenberg JE, Hahn NM, Galsky MD, Vogelzang NJ (2010) Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol 11(9):861–870. doi:10.1016/S1470-2045(10)70086-3
Bellmunt J, Theodore C, Demkov T et al (2009) Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27(27):4454–4461
Galsky MD, Chowdhury S, Bellmunt J et al (2013) Treatment patterns and outcomes in “real world” patients (pts) with metastatic urothelial cancer (UC). ASCO Meet Abstr 31((15_suppl)):4525
Kurata T (2009) Amrubicin for the treatment of advanced lung cancer. Expert Opin Drug Metab Toxicol 5(2):171–180. doi:10.1517/17425250802670508
Jotte R, Conkling P, Reynolds C et al (2011) Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol 29(3):287–293. doi:10.1200/JCO.2010.29.8851
Von Pawel J, Jotte R, Spigel DR et al (2014) Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol 32(35):4012–4019. doi:10.1200/JCO.2013.54.5392
Kuffel MJ, Reid JM, Ames MM (1992) Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother Pharmacol 30(1):51–57
Yamaoka T, Hanada M, Ichii S, Morisada S, Noguchi T, Yanagi Y (1998) Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. Jpn J Cancer Res 89(10):1067–1073
Noguchi T, Ichii S, Morisada S, Yamaoka T, Yanagi Y (1998) Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin. Jpn J Cancer Res 89(10):1061–1066
Noguchi T, Ichii S, Morisada S, Yamaoka T, Yanagi Y (1998) In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite. Jpn J Cancer Res 89(10):1055–1060
Suzuki T, Minamide S, Iwasaki T, Yamamoto H, Kanda H (1997) Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin. Invest New Drugs 15(3):219–225
Noda T, Watanabe T, Kohda A, Hosokawa S, Suzuki T (1998) Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. Invest New Drugs 16(2):121–128
Ohmori H, Yamato T, Asahi T (2001) Phase I study of amrubicin hydrochroride (SM-5887) for superficial bladder cancer in intravesical chemotherapy. Gan To Kagaku Ryoho 28(4):475–482
Tsushima T, Kobashi K, Akebi N et al (2001) Early phase II study of amrubicin (SM-5887) for superficial bladder cancer: a dose-finding study for intravesical chemotherapy. Gan To Kagaku Ryoho 28(4):483–491
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. doi:10.1016/j.ejca.2008.10.026
Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10(1):1–10
Bellmunt J, Choueiri TK, Fougeray R et al (2010) Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 28(11):1850–1855. doi:10.1200/JCO.2009.25.4599
McCaffrey JA, Hilton S, Mazumdar M et al (1997) Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 15(5):1853–1857
Witte RS, Elson P, Bono B et al (1997) Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 15(2):589–593
Sweeney CJ, Roth BJ, Kabbinavar FF et al (2006) Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 24(21):3451–3457
Culine S, Theodore C, De Santis M et al (2006) A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 94(10):1395–1401. doi:10.1038/sj.bjc.6603118
Powles T, Vogelzang NJ, Fine GD et al (2014) Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). ASCO Meet Abstr 32((15_suppl)):5011
Plimack ER, Bellmunt J, Gupta S et al (2015) Pembrolizumab (MK-3475) for advanced urothelial cancer: updated results and biomarker analysis from KEYNOTE-012. J Clin Oncol 33 (suppl; abstr 4502)
Sequist L V, Cassier P, Varga A et al (2014) Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors. In: American Association for Cancer Research 2014 Annual Meeting, p CT326
Bahleda R, Dienstmann R, Adamo B et al (2014) Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors. ASCO Meet Abstr 32((15_suppl)):2501
Ko Y-J, Canil CM, Mukherjee SD et al (2013) Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. Lancet Oncol 14(8):769–776. doi:10.1016/S1470-2045(13)70162-1
Quinn DI, Ruel N, Twardowski P et al (2015) Eribulin in advanced urothelial cancer (AUC) patients (pts): a California cancer consortium trial–NCI/CTEP 7435. ASCO Meet Abstr 33((15_suppl)):4504
Van Allen EM, Mouw KW, Kim P et al (2014) Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 4(10):1140–1153. doi:10.1158/2159-8290.CD-14-0623
Plimack ER, Dunbrack RL, Brennan TA et al (2015) Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur Urol. doi:10.1016/j.eururo.2015.07.009
Sonpavde G, Pond GR, Fougeray R et al (2013) Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol 63(4):717–723. doi:10.1016/j.eururo.2012.11.042
Acknowledgments
This study was supported by grant UL1TR000067 from the National Center for Research Resources, National Institutes of Health. M.D.G has received research funding from Celgene, Novartis, BMS, Dendreon, and BioMotiv and has served as an advisor to Novartis, Genentech, and Merck. He is a co-founder of Dual Therapeutics.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Galsky, M.D., Hahn, N.M., Wong, B. et al. Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma. Cancer Chemother Pharmacol 76, 1259–1265 (2015). https://doi.org/10.1007/s00280-015-2884-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-015-2884-7